Clinical observation of Shuanghuang Shengbai Granule (双黄升白颗粒) on prevention and treatment of myelosuppression caused by chemotherapy in cancer patients

Li-fang Wang; Zhen-ye Xu; Zhong-qi Wang; Ming Zhang; Gui-ying Yan; An-ji Hou; Hai-bin Deng; Ji Wu; Xiao-zhen Zhao; Yi Xiang; Lei Yu

doi:10.1007/s11655-016-2503-4

Your Location：

Home >

Browse articles >

Clinical observation of Shuanghuang Shengbai Granule (双黄升白颗粒) on prevention and treatment of myelosuppression caused by chemotherapy in cancer patients

Updated：2021-08-27

- Clinical observation of Shuanghuang Shengbai Granule (双黄升白颗粒) on prevention and treatment of myelosuppression caused by chemotherapy in cancer patients
- Chinese Journal of Integrative Medicine Vol. 23, Issue 2, Pages: 105-109(2017)
- Affiliations：
  
  1. Department of Oncology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine,Shanghai,China
  2. Department of Integrated Medicine, Shanghai Chest Hospital,Shanghai,China
  3. Department of Oncology, Shanghai Punan Hospital of Pudong New District,Shanghai,China
  4. Department of Oncology, Shanghai Seventh People’s Hospital,Shanghai,China
- Author bio：
- Funds：
  
  Supported by National Natural Science Foundation of China (No. 81202670), and Project of Longhua Medical Team Shanghai, China (No. LYTD-18)
- DOI：10.1007/s11655-016-2503-4
  CLC：
- Published：2017，
  
  Published Online：2 August 2016，
Scan for full text
Wang, Lf., Xu, Zy., Wang, Zq. et al. Clinical observation of Shuanghuang Shengbai Granule (双黄升白颗粒) on prevention and treatment of myelosuppression caused by chemotherapy in cancer patients., Chin. J. Integr. Med. 23, 105–109 (2017). https://doi.org/10.1007/s11655-016-2503-4

Li-fang Wang, Zhen-ye Xu, Zhong-qi Wang, et al. Clinical observation of Shuanghuang Shengbai Granule (双黄升白颗粒) on prevention and treatment of myelosuppression caused by chemotherapy in cancer patients. [J]. Chinese Journal of Integrative Medicine 23(2):105-109(2017)
Wang, Lf., Xu, Zy., Wang, Zq. et al. Clinical observation of Shuanghuang Shengbai Granule (双黄升白颗粒) on prevention and treatment of myelosuppression caused by chemotherapy in cancer patients., Chin. J. Integr. Med. 23, 105–109 (2017). https://doi.org/10.1007/s11655-016-2503-4 DOI：

Li-fang Wang, Zhen-ye Xu, Zhong-qi Wang, et al. Clinical observation of Shuanghuang Shengbai Granule (双黄升白颗粒) on prevention and treatment of myelosuppression caused by chemotherapy in cancer patients. [J]. Chinese Journal of Integrative Medicine 23(2):105-109(2017) DOI： 10.1007/s11655-016-2503-4.

摘要

To study the efficacy and safety of Shuanghuang Shengbai Granule (双黄升白颗粒

SSG)

a traditional Chinese herbal medicine

on myelosuppression of cancer patients caused by chemotherapy. A total of 330 patients were randomly assigned to the treatment group (220 cases

analysed 209 cases) and the control group (110 cases

analysed 102 cases) with a 2:1 ratio by envelope method. The patients in the treatment group at the first day of chemotherapy started to take SSG for 14 days

while the patients in the control group took Leucogon Tablets. The changes of the blood routine

clinical symptoms and immune function in both groups were observed for safety and efficacy evaluation. At the 7th day of chemotherapy

the white blood cells (WBCs) level in the treatment group was significantly higher than that in the control group (P<0.05). After treatment

the WBCs rate in the normal range accounted for 50.2% in the treatment group

the myelosuppression of WBCs and neutrophil were mainly grade I

while 8.1% and 5.7% of patients emerged grade III and grade IV myelosuppression

respectively. The incidence of myelosuppression of the treatment group was significantly lower than that of the control group (P<0.05). The total effective rate of Chinese medicine syndrome in the treatment group was significantly higher than that in the control group (84.2% vs. 72.5%

P<0.05). The immune cell levels in both groups were maintained in the normal range. Compared with that before treatment

the levels of CD3+ and CD4+ cells were significantly increased in the treatment group after treatment (P<0.05). The discrepancy of CD3+ and CD4+ cell activity before and after treatment in both groups were significantly different (P<0.05). No obvious adverse event occurred in both groups. SSG had a protection effect on bone marrow suppression

and alleviated the clinical symptoms together with clinical safety.

Abstract